{"mainPropery":{"diseaseId":9574,"diseaseName":"Clear cell renal cell carcinoma","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/9574/clear-cell-renal-cell-carcinoma","synonyms":["Clear cell RCC","Cystic-multilocular variant","Clear-cell metastatic renal cell carcinoma (subtype)"],"synonyms-with-source":[{"name":"Clear cell RCC"},{"name":"Cystic-multilocular variant"},{"name":"Clear-cell metastatic renal cell carcinoma (subtype)"}],"identifiers":[]},"diseaseCategories":[{"diseaseTypeId":1,"diseaseTypeName":"Rare Cancers"}],"organizations":[],"resource descriptions":[{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=%28Clear%5BTitle%5D%20AND%20cell%5BTitle%5D%20AND%20renal%5BTitle%5D%20AND%20cell%5BTitle%5D%20AND%20carcinoma%5BTitle%5D%29%20AND%20hasabstract%5Btext%5D%20AND%20English%5BLang%5D%20AND%20%22humans%22%5BMeSH%20Terms%5D%20AND%20%222004/08/31%2010.26%22%5BEDAT%5D%20%3A%20%222005/08/31%2010.26%22%5BEDAT%5D' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Clear cell renal cell carcinoma. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22Clear+cell+renal+cell+carcinoma%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Clear cell renal cell carcinoma. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/DOID:4467' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2160,"resourceId":3368,"resourceName":"Patient Access Network Foundation","descriptionText":"<a href='https://panfoundation.org/index.php/en/patients/assistance-programs/renal-cell-carcinoma' target='_blank'>Patient Access Network Foundation</a> (PAN Foundation) has Assistance Programs for those with health insurance who reside in the United States. The disease fund status can change over time, so you may need to check back if funds are not currently available.&nbsp;","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"},{"id":2162,"resourceId":3371,"resourceName":"The Assistance Fund","descriptionText":"<a href='https://tafcares.org/patients/covered-diseases/' target='_blank'>The Assistance Fund</a> provides various services, including education and financial aid, to help patients with a chronic or serious illness cover the cost of FDA-approved medications. Patients must be U.S citizens or permanent residents.","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"}],"overviewQuestion":{"questionId":6231,"questionText":"What is clear cell renal cell carcinoma?","answerText":"<strong>Clear cell renal cell carcinoma</strong> is a cancer of the <a href=\"http://www.nlm.nih.gov/medlineplus/ency/imagepages/1101.htm\" target=_blank>kidney</a>.&nbsp; The name \"clear cell\" refers to the appearance of the cancer cells when viewed with a microscope.[5258]&nbsp; Clear cell renal cell carcinoma occurs when cells in the kidney quickly increase in number, creating a lump (<a href=\"http://www.cancer.gov/dictionary?CdrID=638197\" target=_blank>mass</a>).&nbsp;&nbsp;Though the exact cause of clear cell renal cell carcinoma is unknown, smoking, the excessive use of certain medications, and several <a href=\"https://ghr.nlm.nih.gov/primer/mutationsanddisorders/predisposition\" target=_blank>genetic predisposition</a> conditions (such as <a href=\"http://rarediseases.info.nih.gov/GARD/Condition/7855/Von_Hippel_Lindau_disease.aspx\" target=_blank>von Hippel Lindau syndrome</a>) may contribute to the development of this type of cancer.&nbsp; Treatment often begins with surgery to remove as much of the cancer as possible, and may be followed by <a href=\"http://www.cancer.gov/dictionary?CdrID=44971\" target=_blank>radiation therapy</a>, <a href=\"http://www.cancer.gov/dictionary?CdrID=45214\" target=_blank>chemotherapy</a>, <a href=\"http://www.cancer.gov/dictionary?CdrID=45617\" target=_blank>biological therapy</a>, or <a href=\"http://www.cancer.gov/dictionary?CdrID=270742\" target=_blank>targeted therapy</a>.[5257]","dateModified":"2012-06-01T23:13:00"},"basicQuestions":[{"questionId":6229,"questionText":"What treatments for metastatic clear cell renal cell carcinoma are available in North America?","answerText":"There are several treatments for metastatic clear cell renal cell carcinoma available in North America.&nbsp; <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a692009.html\" target=_blank>IL-2</a> and <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a607052.html\" target=_blank>sunitinib</a> -&nbsp;as well as the medications <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a607071.html\" target=_blank>temsirolimus</a>, <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a607001.html\" target=_blank>bevacizumab</a>&nbsp;with&nbsp;<a href=\"http://www.cancer.gov/cancertopics/factsheet/Therapy/biological\" target=_blank>interferon therapy</a>, <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a610013.html\" target=_blank>pazopanib</a>, and <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a607051.html\" target=_blank>sorafenib</a> - are approved by the <a href=\"http://www.fda.gov/\" target=_blank>Food and Drug Administration</a> for the treatment of metastatic clear cell renal cell carcinoma.[5255]&nbsp; Because a cure for this disease has yet to be discovered, the <a href=\"http://www.cancer.gov/\" target=_blank>National Cancer Institute</a> suggests that individuals with metastatic clear cell renal cell carcinoma consider participation in a research study.[5254]<br><br>IL-2 is offered as a treatment for this disease in some individuals because it has been shown to cause a complete disappearance&nbsp;of signs of this disease (<a href=\"http://www.cancer.gov/dictionary?CdrID=45867\" target=_blank>remission</a>) in 5% of treated patients.[5254]&nbsp; As IL-2 may cause toxic side effects, it is most appropriate for patients who are in excellent health.[5255]&nbsp; <br><br>Sunitinib is offered because it has been shown to stabilize metastatic clear cell renal cell carcinoma by stopping the disease from getting worse.&nbsp; Individuals treated with sunitinib showed no change in their disease for an average of 11 months.[5254]","dateModified":"2012-06-01T22:39:00","resourceClassificationName":"Treatment","references":[{"referenceId":5254,"authors":"National Cancer Institute","articleTitle":"Stage IV and Recurrent Renal Cell Cancer","bookWebsiteJournalTitle":"Renal Cell Cancer Treatment","date":"2012","url":"http://www.cancer.gov/cancertopics/pdq/treatment/renalcell/HealthProfessional/page8","dateAccessed":"2012-05-31T00:00:00"},{"referenceId":5255,"authors":"National Comprehensive Cancer Network","articleTitle":"Kidney Cancer","bookWebsiteJournalTitle":"NCCN Clinical Practic Guidelines in Oncology","date":"2012","url":"http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf","dateAccessed":"2012-05-31T00:00:00"}]}],"references":[],"relatedDiseases":[],"gardCases":[{"caseId":35346,"abbreviatedInquiry":"I have read that IL-2 is no longer the standard treatment for metastatic clear cell renal cell carcinoma.&nbsp; According to the literature, it is no longer used in Europe.&nbsp; Is this&nbsp;true in North America?&nbsp; Is sunitinib now prescribed as treatment in North America?","caseQuestions":[{"questionId":6229,"questionText":"What treatments for metastatic clear cell renal cell carcinoma are available in North America?","answerText":"There are several treatments for metastatic clear cell renal cell carcinoma available in North America.&nbsp; <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a692009.html\" target=_blank>IL-2</a> and <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a607052.html\" target=_blank>sunitinib</a> -&nbsp;as well as the medications <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a607071.html\" target=_blank>temsirolimus</a>, <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a607001.html\" target=_blank>bevacizumab</a>&nbsp;with&nbsp;<a href=\"http://www.cancer.gov/cancertopics/factsheet/Therapy/biological\" target=_blank>interferon therapy</a>, <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a610013.html\" target=_blank>pazopanib</a>, and <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a607051.html\" target=_blank>sorafenib</a> - are approved by the <a href=\"http://www.fda.gov/\" target=_blank>Food and Drug Administration</a> for the treatment of metastatic clear cell renal cell carcinoma.[5255]&nbsp; Because a cure for this disease has yet to be discovered, the <a href=\"http://www.cancer.gov/\" target=_blank>National Cancer Institute</a> suggests that individuals with metastatic clear cell renal cell carcinoma consider participation in a research study.[5254]<br><br>IL-2 is offered as a treatment for this disease in some individuals because it has been shown to cause a complete disappearance&nbsp;of signs of this disease (<a href=\"http://www.cancer.gov/dictionary?CdrID=45867\" target=_blank>remission</a>) in 5% of treated patients.[5254]&nbsp; As IL-2 may cause toxic side effects, it is most appropriate for patients who are in excellent health.[5255]&nbsp; <br><br>Sunitinib is offered because it has been shown to stabilize metastatic clear cell renal cell carcinoma by stopping the disease from getting worse.&nbsp; Individuals treated with sunitinib showed no change in their disease for an average of 11 months.[5254]","dateModified":"2012-06-01T22:39:00","resourceClassificationName":"Treatment","references":[{"referenceId":5254,"authors":"National Cancer Institute","articleTitle":"Stage IV and Recurrent Renal Cell Cancer","bookWebsiteJournalTitle":"Renal Cell Cancer Treatment","date":"2012","url":"http://www.cancer.gov/cancertopics/pdq/treatment/renalcell/HealthProfessional/page8","dateAccessed":"2012-05-31T00:00:00"},{"referenceId":5255,"authors":"National Comprehensive Cancer Network","articleTitle":"Kidney Cancer","bookWebsiteJournalTitle":"NCCN Clinical Practic Guidelines in Oncology","date":"2012","url":"http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf","dateAccessed":"2012-05-31T00:00:00"}]},{"questionId":6230,"questionText":"How can I learn about research involving metastatic clear cell renal cell carcinoma?","answerText":"<p>The U.S. National Institutes of Health, through the National Library of Medicine, developed <a href=\"http://www.clinicaltrials.gov/\">ClinicalTrials.gov</a> to provide patients, family members, and members of the public with current information on clinical research studies. Currently,&nbsp;38 clinical trials are identified as enrolling individuals with <a href=\"http://clinicaltrials.gov/ct2/results?term=metastatic+clear+cell+renal+cell+carcinoma&amp;recr=Open\" target=_blank>metastatic clear cell renal cell carcinoma</a>.&nbsp; To find these trials, click on the link in the previous sentence. After you click on a study, review its \"eligibility\" criteria to determine its appropriateness. Use the study’s contact information to learn more. Check this site often for regular updates.</p>\r\n<p>You can also contact the Patient Recruitment and Public Liaison (PRPL) Office at the National Institutes of Health (NIH). We recommend calling 1-800-411-1222 to speak with a specialist, who can help you determine if you are eligible for any clinical trials. If you are&nbsp;located outside the United States, and would like to be contacted via telephone, you will need to&nbsp;contact PRPL and provide your telephone&nbsp;number in full, including area code&nbsp;and international&nbsp;dialing prefix.</p>\r\n<p>Patient Recruitment and Public Liaison Office<br>NIH Clinical Center<br>Bethesda, Maryland 20892-2655<br>Toll-free: 1-800-411-1222<br>Fax: 301-480-9793<br>E-mail: <a href=\"mailto:prpl@mail.cc.nih.gov\">prpl@mail.cc.nih.gov</font></a><br>Web site:&nbsp; </font><a href=\"http://clinicalcenter.nih.gov/\">http://clinicalcenter.nih.gov/</font></a> </p>\r\n<p>If you are interested in enrolling in a clinical trial, you can find helpful general information on clinical trials at the <a href=\"http://clinicaltrials.gov/ct2/info/understand\">ClinicalTrials.gov</a> Web page. Resources on many charitable or special-fare flights to research and treatment sites and low-cost hospitality accommodations for outpatients and family members, as well as ambulance services, are listed on the Web site of the <a href=\"http://rarediseases.info.nih.gov/Resources.aspx?PageID=8\">Office of Rare Diseases Research (ORDR)</a>, part of the National Institutes of Health.</p>","dateModified":"2012-06-01T22:39:00","references":[]}]}],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[],"medicalProducts":[{"productId":51,"genericName":"Sorafenib","tradeName":"Nexavar","tradeLink":"http://www.nexavar-us.com/","manufacturer":"","sponsor":"Bayer Pharmaceutical Corporation","indication":"Treatment of patients with advanced renal cell carcinoma.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/rn/475207-59-1","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a607051.html"},{"productId":101,"genericName":"Aldesleukin","tradeName":"Proleukin®","tradeLink":"https://www.proleukin.com/","manufacturer":"","sponsor":"Chiron Corporation","indication":"Treatment of adults (>18 years old) with metastatic renal cell carcinoma.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/Proleukin","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a692009.html"},{"productId":482,"genericName":"Temsirolimus","tradeName":"Torisel®","tradeLink":"http://torisel.com/","manufacturer":"","sponsor":"Wyeth Pharmaceuticals, Inc.","indication":"Treatment of advanced renal cell carcinoma","drugInformationLink":"http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Torisel","medlinePlusLink":"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a607071.html"}],"EncodedName":"Clear_cell_renal_cell_carcinoma"}